{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:52:49Z","timestamp":1792623169997,"version":"4.5.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Macrophage activation syndrome (MAS), a secondary form of hemophagocytic lymphohistiocytosis, is a serious life-threatening complication associated with systemic juvenile idiopathic arthritis (sJIA). MAS is characterized by fever, hepatosplenomegaly, liver dysfunction, cytopenias, coagulation abnormalities, and hyperferritinemia and may progress to multiple organ failure and death. Overproduction of interferon-gamma is a major driver of hyperinflammation in murine models of MAS and primary hemophagocytic lymphohistiocytosis. A subset of patients with sJIA may develop progressive interstitial lung disease, which is often difficult to manage. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can potentially be a curative immunomodulatory strategy for patients with sJIA refractory to conventional therapy and\/or complicated by MAS. The use of emapalumab (anti-interferon gamma antibody) for the active control of MAS in refractory cases of sJIA and associated lung disease has not been reported. Herein we report a patient with refractory sJIA complicated by recurrent MAS and lung disease that was managed with emapalumab and ultimately followed by an allo-HSCT, which resulted in permanent correction of the underlying immune dysregulation and improvement of lung disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Report<\/jats:title><jats:p>We present a 4-year-old girl with sJIA complicated by recurrent MAS and progressive interstitial lung disease. She developed a progressively worsening disease that was refractory to glucocorticoids, anakinra, methotrexate, tocilizumab, and canakinumab. She had a chronic elevation of serum inflammatory markers, notably soluble interleukin-18, and CXC chemokine ligand 9 (CXCL9). Emapalumab, initiated at 6\u2005mg\/kg (1 dose) and continued at 3\u2005mg\/kg twice weekly for a total of 4 weeks, resulted in MAS remission along with normalization of inflammatory markers. The patient received a matched sibling donor allo-HSCT after a reduced-intensity conditioning regimen with fludarabine\/melphalan\/thiotepa and alemtuzumab, along with tacrolimus and mycophenolate mofetil for graft-vs.-host disease prophylaxis. At 20 months following her transplant, she has maintained a full donor engraftment with complete donor-derived immune reconstitution. She had complete resolution of sJIA symptoms including marked improvement in her lung disease along with normalization of serum interleukin-18 and CXCL9 levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The use of emapalumab followed by allo-HSCT could help achieve a complete response in refractory cases of sJIA complicated by MAS who have failed standard treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2023.1123104","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T06:13:17Z","timestamp":1676873597000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Case report: Emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome"],"prefix":"10.3389","volume":"11","author":[{"given":"Deepak","family":"Chellapandian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Milojevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/ncprheum0084","article-title":"Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome","volume":"2","author":"Woo","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","article-title":"Macrophage activation syndrome in the era of biologic therapy","volume":"12","author":"Grom","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B3","first-page":"390","article-title":"International league of associations for rheumatology. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/gene.2012.3","article-title":"Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment","volume":"13","author":"Ravelli","year":"2012","journal-title":"Genes Immun"},{"key":"B5","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3899\/jrheum.141261","article-title":"Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"42","author":"Minoia","year":"2015","journal-title":"J Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/acr.23277","article-title":"Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis","volume":"70","author":"Schulert","year":"2018","journal-title":"Arthritis Care Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1002\/art.41073","article-title":"Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors","volume":"71","author":"Schulert","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/acr.21889","article-title":"Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis","volume":"65","author":"Kimura","year":"2013","journal-title":"Arthritis Care Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1182\/bloodadvances.2017014449","article-title":"Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis","volume":"2","author":"Silva","year":"2018","journal-title":"Blood Adv"},{"key":"B11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3899\/jrheum.180168","article-title":"Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus","volume":"46","author":"Martini","year":"2019","journal-title":"J Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/annrheumdis-2020-eular.3169","article-title":"OP0290 Emapalumab (anti-interferon-gamma monoclonal antibody) in patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (sJIA)","volume":"79","author":"De Benedetti","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.autrev.2017.10.007","article-title":"HLA-DRB1 alleles and juvenile idiopathic arthritis: diagnostic clues emerging from a meta-analysis","volume":"16","author":"De Silvestri","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jaut.2015.08.002","article-title":"Immunogenetics of juvenile idiopathic arthritis: a comprehensive review","volume":"64","author":"Hersh","year":"2015","journal-title":"J Autoimmun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2021-220578","article-title":"Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles","volume":"81","author":"Saper","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1123104\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T06:13:20Z","timestamp":1676873600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1123104\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":15,"alternative-id":["10.3389\/fped.2023.1123104"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1123104","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]},"article-number":"1123104"}}